A Study of LY2409021 in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug after the dose. This study will last approximately 28 days, not including screening. Screening can occur within 30 days prior to the start of the study.

Key facts

Study ID

NCT02217618

Run by

Eli Lilly and Company

People needed

16

Starts

2014-08-01

Expected to finish

2014-09-01

Last updated by the study team

2018-10-29

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or females as determined by medical history
• Satisfactory clinical laboratory and physical examination tests
• Have a body mass index (BMI) of 18 to 32.0 kilograms per meter squared (kg/m\^2)

You may not qualify if…

• Abnormal electrocardiograms (ECGs)

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Daytona Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.